Citigroup Inc Cullinan Oncology, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Citigroup Inc holds 38,388 shares of CGEM stock, worth $516,318. This represents 0.0% of its overall portfolio holdings.

Number of Shares

38,388

Previous 22,107 73.65%

Holding current value

$516,318

Previous $385,000 66.75%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$16.03 - $20.86 $260,984 - $339,621	16,281 Added 73.65%	38,388 $642,000
Q2 2024 Aug 12, 2024	SELL	$15.63 - $29.35 $991,989 - $1.86 Million	-63,467 Reduced 74.17%	22,107 $385,000
Q1 2024 May 10, 2024	BUY	$10.17 - $19.02 $762,790 - $1.43 Million	75,004 Added 709.59%	85,574 $1.46 Million
Q4 2023 Feb 09, 2024	SELL	$7.89 - $10.23 $102,285 - $132,621	-12,964 Reduced 55.09%	10,570 $107,000
Q3 2023 Nov 09, 2023	BUY	$9.05 - $11.72 $138,537 - $179,409	15,308 Added 186.09%	23,534 $212,000
Q2 2023 Aug 10, 2023	SELL	$8.8 - $13.4 $79,314 - $120,774	-9,013 Reduced 52.28%	8,226 $88,000
Q1 2023 May 11, 2023	BUY	$10.2 - $11.91 $164,352 - $191,905	16,113 Added 1430.99%	17,239 $176,000
Q4 2022 Feb 09, 2023	SELL	$9.72 - $13.62 $2,012 - $2,819	-207 Reduced 15.53%	1,126 $11,000
Q3 2022 Nov 10, 2022	SELL	$11.82 - $15.42 $21,157 - $27,601	-1,790 Reduced 57.32%	1,333 $17,000
Q2 2022 Aug 10, 2022	SELL	$7.31 - $13.55 $55,804 - $103,440	-7,634 Reduced 70.97%	3,123 $40,000
Q1 2022 May 12, 2022	SELL	$10.47 - $16.75 $522,672 - $836,176	-49,921 Reduced 82.27%	10,757 $113,000
Q4 2021 Feb 10, 2022	BUY	$15.36 - $25.0 $883,307 - $1.44 Million	57,507 Added 1813.53%	60,678 $936,000
Q3 2021 Nov 10, 2021	BUY	$22.56 - $29.68 $71,537 - $94,115	3,171 New	3,171 $72,000

Others Institutions Holding CGEM

# of Institutions

146

Shares Held

67.6M

Call Options Held

612K

Put Options Held

118K

View Full List

About Cullinan Oncology, Inc.

Ticker CGEM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,612,200
Market Cap $613M
Description
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...

More about CGEM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account